Table 1.
Patient characteristics
| N | % | |
|---|---|---|
| No. of patients | 31 | |
| Gender | ||
| Male | 15 | 48 |
| Female | 16 | 52 |
| Race | ||
| Caucasian | 30 | 97 |
| Asian | 1 | 3 |
| Median age (years) | 63 | |
| Range | 37–77 | |
| Stage | ||
| Metastatic | 29 | 94 |
| Locally advanced | 2 | 6 |
| WHO performance status | ||
| 0 | 16 | 52 |
| 1 | 11 | 35 |
| 2 | 4 | 13 |
| Histology | ||
| Adenocarcinoma | 30 | 97 |
| Acinar cell carcinoma | 1 | 3 |
| Prior therapy | ||
| First line | 15 | 48 |
| Neoadjuvant CRT | 1 | 3 |
| Adjuvant gemcitabine | 1 | 3 |
| Second line | 16 | 52 |
| Adjuvant gemcitabinea | 5 | 16 |
| Palliative | 11 | 35 |
WHO World Health Organization, CRT chemoradiotherapy
aProgression during or within 6 months after adjuvant treatment